Cargando…
Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HI...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503669/ https://www.ncbi.nlm.nih.gov/pubmed/36146831 http://dx.doi.org/10.3390/v14092025 |
_version_ | 1784796022974709760 |
---|---|
author | Emert-Sedlak, Lori A. Shi, Haibin Tice, Colin M. Chen, Li Alvarado, John J. Shu, Sherry T. Du, Shoucheng Thomas, Catherine E. Wrobel, Jay E. Reitz, Allen B. Smithgall, Thomas E. |
author_facet | Emert-Sedlak, Lori A. Shi, Haibin Tice, Colin M. Chen, Li Alvarado, John J. Shu, Sherry T. Du, Shoucheng Thomas, Catherine E. Wrobel, Jay E. Reitz, Allen B. Smithgall, Thomas E. |
author_sort | Emert-Sedlak, Lori A. |
collection | PubMed |
description | While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs. |
format | Online Article Text |
id | pubmed-9503669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95036692022-09-24 Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor Emert-Sedlak, Lori A. Shi, Haibin Tice, Colin M. Chen, Li Alvarado, John J. Shu, Sherry T. Du, Shoucheng Thomas, Catherine E. Wrobel, Jay E. Reitz, Allen B. Smithgall, Thomas E. Viruses Review While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs. MDPI 2022-09-13 /pmc/articles/PMC9503669/ /pubmed/36146831 http://dx.doi.org/10.3390/v14092025 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Emert-Sedlak, Lori A. Shi, Haibin Tice, Colin M. Chen, Li Alvarado, John J. Shu, Sherry T. Du, Shoucheng Thomas, Catherine E. Wrobel, Jay E. Reitz, Allen B. Smithgall, Thomas E. Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor |
title | Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor |
title_full | Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor |
title_fullStr | Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor |
title_full_unstemmed | Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor |
title_short | Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor |
title_sort | antiretroviral drug discovery targeting the hiv-1 nef virulence factor |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503669/ https://www.ncbi.nlm.nih.gov/pubmed/36146831 http://dx.doi.org/10.3390/v14092025 |
work_keys_str_mv | AT emertsedlakloria antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT shihaibin antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT ticecolinm antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT chenli antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT alvaradojohnj antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT shusherryt antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT dushoucheng antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT thomascatherinee antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT wrobeljaye antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT reitzallenb antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor AT smithgallthomase antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor |